Formulation And Evaluation of Self Micro Emulsifying Drug Delivery System on Metformin Hydrochloride

For the treatment of type 2 diabetes mellitus, metformin hydrochloride is a commonly prescribed antidiabetic medication. Due to low permeability and high hydrophilicity, its oral bioavailability is low, which restricts its therapeutic efficacy. A Self-Microemulsifying Drug Delivery System (SMEDDS) was created in order to overcome these obstacles by improving the solubility and gastrointestinal absorption of Metformin. The Smix ratio constant at 2:1, the formulations were created using Tween 20 as the surfactant, propylene glycol as the co-surfactant, and castor oil as the oil phase. The oil concentration was changed to create a total of six formulations (F1–F6). The physical appearance, self-emulsification time, droplet size analysis, zeta potential, transmittance, viscosity, drug content uniformity, and in vitro drug release utilizing simulated gastric fluid were all examined in detail for each formulation. The appropriate microemulsion areas were determined using pseudo-ternary phase diagrams. Dynamic light scattering (DLS) and UV spectrophotometry were used to measure droplet size and drug concentration, respectively. The main goal was to create an oral delivery method that was both stable and effective at improving the pharmacokinetic profile of Metformin. According to the study, SMEDDS is a viable and successful method for increasing the solubility, permeability, and therapeutic effectiveness of hydrophilic antidiabetic medications, such as Metformin hydrochloride.